InMed Pharmaceuticals (INM) Operating Expenses (2019 - 2026)

InMed Pharmaceuticals has reported Operating Expenses for 8 years, with the latest figure at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 36.28% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $10.4 million (up 9.11% YoY), and the FY2025 full-year result was $9.7 million, up 3.83% from the prior year.
• Operating Expenses for Q1 2026 stood at $2.8 million, up from $2.3 million in the prior quarter.
• The five-year high for Operating Expenses was $6.8 million in Q2 2022, with the low at $2.0 million in Q4 2023.
• Historically, Operating Expenses has averaged $2.8 million across 5 years, with a median of $2.3 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 104.75% — and 2023, when it sank 69.64%.
• InMed Pharmaceuticals' Operating Expenses stood at $2.3 million in 2022, then dropped by 16.03% to $2.0 million in 2023, then surged by 37.88% to $2.7 million in 2024, then retreated by 15.77% to $2.3 million in 2025, then gained by 24.17% to $2.8 million in 2026.
• The last three Operating Expenses figures came in at $2.8 million (Q1 2026), $2.3 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.